AVTR Avantor, Inc.
Laboratory Analytical Instruments · NYSE · SEC CIK 1722482 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.9%
TTM net income YoY510.2%
TTM EPS YoY484.6%
Revenue 3-yr CAGR-1.9%
Net income 3-yr CAGR-2.5%
Margins
Gross margin31.6%
Operating margin7.3%
Net margin5.1%
FCF margin6.6%
EBITDA margin13.7%
Returns
ROE5.9%
ROA2.9%
ROIC (approx.)5.3%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets49.8%
Debt / equity0.63x
Current ratio1.89x
Interest coverage3.00x
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.55B | $6.78B |
| Cost of revenue | $4.41B | $4.50B |
| Gross profit | $2.14B | $2.28B |
| SG&A expense | $1.60B | $1.64B |
| Operating income | -$246.20M | $1.08B |
| Interest expense | $169.80M | $218.80M |
| Pretax income | -$441.30M | $853.90M |
| Income tax | $88.90M | $142.40M |
| Net income | -$530.20M | $711.50M |
| EBITDA | $164.00M | $1.49B |
| EPS (basic) | -0.78 | 1.05 |
| EPS (diluted) | -0.78 | 1.04 |
| Weighted avg. shares (diluted) | 680.60M | 681.90M |
| Balance sheet | ||
| Cash & equivalents | $365.40M | $264.70M |
| Receivables | $1.07B | $1.03B |
| Inventory | $818.20M | $731.50M |
| Current assets | $2.45B | $2.15B |
| PP&E, net | $766.80M | $708.10M |
| Goodwill | $4.99B | $5.54B |
| Intangibles | $3.10B | $3.27B |
| Total assets | $11.79B | $12.11B |
| Current liabilities | $1.38B | $2.01B |
| Short-term debt | $30.80M | $821.10M |
| Long-term debt | $3.92B | $3.23B |
| Total debt | $3.95B | $4.06B |
| Total liabilities | $6.23B | $6.16B |
| Shareholders' equity | $5.57B | $5.96B |
| Net debt | $3.58B | $3.79B |
| Shares outstanding | 682.00M | 680.80M |
| Cash flow statement | ||
| Operating cash flow | $623.80M | $840.80M |
| Capital expenditure | $128.80M | $148.80M |
| Free cash flow | $495.00M | $692.00M |
| Investing cash flow | -$130.50M | $438.90M |
| Financing cash flow | -$409.40M | -$1.28B |
| Depreciation & amortization | $410.20M | $405.50M |
| Stock-based compensation | $46.40M | $46.80M |
| Share buybacks | $75.10M | $0 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.